The study was set up to determine the clinical value of dihydroxyphenylalanine positron emission tomography-computed tomography ([ 18 F]DOPA PET-CT) in patients with neuroendocrine tumors (NETs). Eighty-two patients with suspected/known NET were imaged with PET(-CT) using [ 18 F] DOPA. Patients were divided into two groups: primary diagnosis/staging and restaging of disease. All patients without previous diagnosis of NET had biochemical proof of disease. The diagnostic accuracy of PET was assessed by comparing the histopathology and clinical follow-up. The overall accuracy of [ 18 F]DOPA PET was 90%. In patients having PET for primary diagnosis/staging (nZ32), the accuracy of PET was 88%, and for restaging 92% (nZ61). The mean S.D. sizes of primary and metastatic lesions detected by PET were 26G11 and 16G9 mm respectively. In organ-region-specific analysis, the sensitivity and specificity were 100% in the primary diagnosis of pheochromocytoma (nZ16) and metastases were found in all cases with recurrent disease (nZ5). The accuracy for NET of gastrointestinal tract was 92% in restaging (nZ24). For the NETs located in the head-neck-thoracic region (nZ19), the overall accuracy of PET was 89% including 12 cases of recurrent medullary thyroid cancer with a sensitivity of 90%. In analysis of patients with biochemical proof of disease combined with negative conventional imaging methods, PET had positive and negative predictive value of 92% and 95% respectively. [
Introduction
Neuroendocrine tumors (NETs) are a heterogeneous group of rare tumors arising from diffuse cells. These tumors are usually relatively slow growing with low malignant potential, but have functional characteristics that can produce pronounced endocrine-related symptoms despite their small size. NETs are located mainly (90%) in the gastrointestinal tract and the pancreas (gastroenteropancreatic NETs). They can also be found in various other sites such as the bronchopulmonary system, the adrenal medulla (pheochromocytoma), the extra-adrenal paraganglia (paraganglioma), and the head-neck region (e.g., neuroblastoma, medullary thyroid cancer (MTC)). The incidence of NETs (2/100 000 for men and 2.4/100 000 for women) is believed to be higher than reported, primarily due to the substantial number of undetected and misclassified tumors (Kloppel et al. 2007 , Modlin et al. 2008 .
Since surgery is the only curative approach in NET, early detection and accurate staging of the disease are essential to establish the treatment and prognosis of the disease. Several imaging modalities are available for patients with a suspected NET such as anatomical imaging by computed tomography (CT) and magnetic resonance imaging (MRI) combined with functional whole-body imaging by scintigraphy with labeled analogues of somatostatin (SRS) and metaiodobenzylguanidine (MIBG). In addition, several recent studies have shown the usefulness of positron emission tomography (PET) in detection, characterization, and staging of NETs.
PET supplies a range of labeled compounds to be used for the characterization of tumor biochemistry. However, the most common tracer in PET imaging, [ 18 F]fluorodeoxyglucose ([ 18 F]FDG), is of limited value in the diagnosis of NETs expect for aggressive form of disease (Jadvar & Segall 1997 , Adams et al. 1998 , Pasquali et al. 1998 . In this context, different tracers have been proposed to visualize NETs and the majority of these experiments have been based on the NET's capacity to take up and decarboxylate amino acid precursors (APUDomas; Pearse 1969) . For example, PET using radiolabeled amine precursors, such as hydroxytryptophan (HTP; Orlefors et al. 2005 , Koopmans et al. 2008 , hydroxyephedrine (Trampal et al. 2004) , dopamine (Pacak et al. 2001) , and dihydroxyphenylalanine (DOPA), has been developed for the localization of NETs. Since the pioneering study of Ahlstrom et al. (1995) using carbon-11-labeled-DOPA, a fluorine-18-labeled analogue [ 18 F]DOPA has been used for the diagnosis of carcinoid tumors (Hoegerle et al. 2001b , Becherer et al. 2004 , Koopmans et al. 2008 , pheochromocytomas (Hoegerle et al. 2002 , Timmers et al. 2007a , insulinomas (Otonkoski et al. 2006 , Kauhanen et al. 2007 , Koopmans et al. 2008 , medullary thyroid carcinomas (Hoegerle et al. 2001a) , and glomus tumors (Hoegerle et al. 2003) .
Despite 
Subjects and methods

Subjects
We analyzed retrospectively the first 119 consecutive patients referred for [ 18 F]DOPA study to our national PET center between January 2000 and March 2007. Ten adult patients with surgically treated insulinoma and b-cell hyperplasia (Kauhanen et al. 2007) , and 14 patients with CHI (congenital hyperinsulinism of infancy) (Otonkoski et al. 2006) , have been reported before and were excluded from the analysis. Furthermore, ten additional patients, who underwent [ 18 F]DOPA PET for primary diagnosis and did not have biochemical proof of disease were excluded from the study. In three patients, complete data were not available, and therefore a total of 82 patients (37 males, 45 females, mean age: 40.5G7.8 years) and 93 PET scans were included in the study. Depending on the indication for PET scanning, study patients were divided into 1) primary diagnosis and staging of disease and 2) restaging of disease. Ten of the study patients had a diagnosis of multiple endocrine neoplasia. The clinical characteristics, biochemical findings, reports of imaging studies, treatments, and follow-up examinations were recorded. The diagnostic accuracy of the PET studies was assessed by comparing the histopathological reports (nZ30) and clinical follow-up (mean: 17.3G11.9 months, nZ63). Demographic data are given in Table 1 . The data collection and analysis were approved by the Institutional Review Board. Patients fasted for at least 6 h before the PET scan. If the patient was on medication that could affect the biodistribution of [
18 F]DOPA (diazoxide, somatostatin analogues, or cortisone), the medication was withdrawn 24 h before the study. In patients with suspicion of a pancreaticoduodenal NET, plasma glucose level was monitored and a glucose (G5-G10%, 40-100 ml/h) infusion was given, if needed, to keep the plasma glucose between 4.0 and 5.0 mmol/l.
The [ 18 F]DOPA PET scans were acquired using PET-CT (Discovery PET-CT; General Electric Medical Systems, Milwaukee, WI, USA; nZ70) and GE Advance (General Electric Medical Systems; nZ33) scanners. [
18 F]DOPA PET was synthesized according to previously described methods (Bergman et al. 1994) . The average administered dose of [ 18 F]DOPA was 234G56 MBq. The decarboxylase inhibitor, carbidopa, was given in 19 patients as a premedication. Scanning began 60 min after tracer injection. Patients underwent a whole-body PET scan from the level of the eyes to the mid-thigh with a GE Advanced PET scanner operated in 2D mode, and after May 2005, scans were acquired on a combined PET-CT. This CT-based scan was used for attenuation correction purposes and to help in anatomic localization of DOPA uptake. Immediately after the CT, an emission PET scan was acquired in 3D mode over the same anatomical regions starting at the level of the mid-thigh.
To obtain images for visual and semi-quantitative analysis, the data were corrected for dead time, decay and photon attenuation, and reconstructed in a 128!128 matrix. The final in-plane resolution in segmented attenuation correction and iterative-reconstructed (SAC-OSEM) and Hann-filtered (4.6 mm) image was 5 mm (full-width half-maximum (FWHM)) when scanned with GE Advance. A fully 3D ML-OS-EM reconstruction algorithm (VuePoint) was used when scanning with PET-CT. The images were reconstructed using two iterations and 28 subsets with a 6.0 mm FWHM post-filter.
PET images were analyzed visually and semiquantitatively by calculating mean and maximum standardized uptake values (SUVs) defined as the ratio of activity per milliliter of tissue to the activity in the injected dose, corrected by decay and per patient's body weight in the region of interest (ROI). ROIs were placed around the regions of increased DOPA uptake for SUV max and SUV mean determination. Any focal tracer accumulation exceeding normal regional tracer uptake was interpreted as a pathological finding. Whenever PET-CT was available, a clear uptake in the area where CT suggested bone fracture or degenerative bone lesions was not regarded as a positive finding. 
Other imaging studies
Data evaluation
The diagnostic accuracy of the PET studies was assessed by comparing the histopathological reports (nZ30) and the imaging findings. When the histology was not available, the consensus was based on the sum of the imaging procedures and follow-up examinations (nZ63). Primary tumor site and axis were taken from the pathology reports if the patient had been operated, and otherwise from imaging studies. All the regions and lesions seen by different imaging modalities were calculated. If the number of lesions was over 10, the number of lesions was truncated at 11 lesions to avoid the bias toward that region.
Statistical analysis
The results are expressed mainly as meansGS.D. The specificity and sensitivity of PET for NET detection were calculated using the pathology results and the clinical follow-up as a gold standard using a 2!2 contingency table. A Mc Nemar test was performed to compare PET and combined CT/MRI (nZ83) and SRS/MIBG scintigraphy (nZ35) results, and k coefficient was determined to quantify agreement of these imaging methods. The Wilcoxon signed-rank test 
Results
Clinical and endocrine status
Patients were divided into five different study groups depending on the indication of PET scanning (Table 1) .
In primary diagnosis and staging, only patients with biochemical proof of disease were included, instead in restaging of known NET also patients with negative biochemistry were included (nZ17). The serum chromogranin A (CgA) levels were significantly increased in 87% of the study patients with a mean level of 60.7 nmol/l (nZ68) (normal value: 18 F]DOPA PET detected a mean value of 0.9 regions and 1.9 lesions more than SRS and MIBG scintigraphy (nZ15) (regions, 3.0 vs 2.1; lesions, 5.5 vs 3.6) (Fig. 1) . Fig. 2 . The accuracy of [ 18 F]DOPA PET was 87% in patients having PET imaging for the primary diagnosis and staging of a NET (nZ32). The mean size of the primary tumors was 26G11 mm. When assessing the organ-regionspecific analysis, both the sensitivity and specificity for pheochromocytoma (nZ16) were 100%. Four out of five primary pheochromocytomas were located in left adrenals, and one in both adrenals in addition to metastatic lymph node in aorta bifurcation was identified in [
18 F]DOPA PET. An accuracy of 50% was achieved in the localization of primary tumors of the GI tract when pancreaticoduodenal tumors were excluded. Furthermore, the sensitivity and specificity in detecting primary pancreaticoduodenal NETs (nZ8) were 67% and 60% respectively. In six patients, [ 18 F]DOPA PET scan was done for suspicion of ectopic ACTH-producing tumors, producing one truepositive and five true-negative findings. (Fig. 3) , while in four patients, the PET scan failed to detect metastasis partly (nZ2) or completely (nZ2). In restaging of disease, the accuracy was 89% for pheochromocytoma (nZ9) and 93% for a GI tract NET (nZ24). Furthermore, in tumors located in the head-neck-thoracic region (nZ19), the overall accuracy of [ 18 F]DOPA PET was 89%, including 12 cases of recurrent MTC with a sensitivity and specificity of 90% and 100% respectively. The sizes of metastatic lesions were 16G9 mm (range: 15-40 mm). 18 F]DOPA in the head of the pancreas. The patient has been in follow-up with moderate symptoms for already 18 months since the second PET scan. Due to the lack of a histological diagnosis, the PET finding in this patient was considered a false-positive result.
Restaging of NET
False-negative and false-positive findings
Discussion
The 
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18 F]DOPA PET-CT of neuroendocrine tumors well-established fact that surgery is the only curative approach in both local and advanced NETs. Even in the case of metastasized disease, it has been shown that the cytoreductive resection of the tumor mass appears to be beneficial and may result in improved long-term recovery in a significant number of patients (Wright et al. 2007) . Furthermore, the extent of tumor spread determines the type of oncological treatment. Thus, an accurate diagnostic tool is of crucial importance for both diagnostic purposes and in planning treatment of NETs. Anatomical imaging (CT and MRI) (Maurea et al. 1993 , Pacak et al. 2001 and functional imaging (SRS and MIBG scintigraphy) (Krenning et al. 1993) had limited sensitivity in the diagnosis of NET. Nowadays, SRS and MIBG scintigraphy are routine in patients with suspicion of a NET and its sensitivity exceeds that of CT and MRI (Krenning et al. 1993, van der Harst et al. 2001) . SRS is based on the expression of somatostatin receptors in endocrine tumors and, therefore, the density of these receptors determines the efficacy of this imaging method. Besides the staging of disease, SRS is used to assess the efficacy of treatment with somatostatin analogue. However, SRS has low sensitivity in localizing small tumors lacking somatostatin receptor 2, which is the case in 20-50% of NETs (Reubi et al. 1994) . Furthermore, the labeled catecholamine analogue MIBG is another well-established tracer for scintigraphy visualization. However, according to a recent review, up to 30% of carcinoid tumors had no accumulation of MIBG (Rufini et al. 2006) , and scintigraphy seems to have limited sensitivity for the diagnosis of metastasized disease due to decreased expression of norepinephrine transporters by less differentiated cells. The sensitivity of MIBG scintigraphy was 57% in metastatic pheochromocytoma, and 92-96% in non-metastatic disease based on a series of 75 patients (van der Harst et al. 2001) .
Initially, [ 18 F]FDG was used as a tracer in PET imaging in the diagnosis of NETs. Accumulation of [ 18 F]FDG in tumors is an index of increased glucose uptake, which reflects tumor aggressiveness, and, therefore, [
18 F]FDG PET is more sensitive in localizing metastatic NETs (Adams et al. 1998 , Timmers et al. 2007b . In ectopic ACTH-secreting NETs, Pacak and co-workers, in a series of 17 patients, reported no advance in localizing tumors using [
18 F]FDG PET compared with conventional imaging (Pacak et al. 2004) , whereas later on, one study reported successful localization of the disease in all three study patients (Kumar et al. 2006) . Moreover, in localizing pheochromocytomas by [
18 F]FDG PET, the sensitivity was 70% for solitary benign or malignant disease (Shulkin et al. 1999) . The lack of sensitivity of [ 18 F]FDG PET in non-metastasized NET led to the studies of specifically targeted tracers that take advantage of the NET-specific catecholamine pathway. Based on the amine precursor uptake and Endocrine-Related Cancer (2009) 16 255-265 www.endocrinology-journals.org decarboxylation systems of the NET, the amine precursor, L-DOPA, was introduced as a specific tracer to image these tumors (Ahlstrom et al. 1995) .
The mechanism that determines the uptake of [ 18 F]DOPA PET in neuroendocrine tissues is not fully understood. Increased activity of L-DOPA decarboxylase was found to be characteristic of NETs (Gazdar et al. 1988) , probably contributing to tracer uptake (Gibril & Jensen 2004 Our results, especially the high sensitivity of 100% for 25 patients with suspected pheochromocytoma, are in concordance with the previous findings. Previously, only one small study using [ 18 F]DOPA PET for the primary diagnosis of NET in 14 patients with pheochromocytoma with a sensitivity up to 100% has been published (Pacak et al. 2001 , Hoegerle et al. 2002 . Furthermore, Hoegerle and co-workers studied 17 patients with carcinoid tumors with a sensitivity of 65% for [ 18 F]DOPA PET imaging compared with anatomical imaging with sensitivity of 73%. Although the anatomical imaging modalities were more sensitive in organ metastases, [
18 F]DOPA PET was better in the localization of primary tumors and lymph node metastases (Hoegerle et al. 2001b) . Subsequently, other studies of advanced-stage carcinoids showed [ 18 F] DOPA PET to be more sensitive than conventional imaging in detecting skeletal lesions (Becherer et al. 2004) , and it also found more tumor lesions per region compared with combined SRS and CT (96 vs 65%; Koopmans et al. 2006) . Our finding is in agreement with these previous studies, since we found that [ 18 F]DOPA PET detected significantly more tumor lesions than combined CT/MRI imaging (P!0.0001). Recently, Montravers and co-workers (Gabriel et al. 2007) .
The main limitation of the present study was the lack of a pathological reference standard, although obtaining a biopsy specimen for histological verification from all participants with negative tests and several lesions is not feasible. Thus, we collected information during follow-up to confirm the truepositive and -negative findings. Another limitation is that conventional imaging studies, especially SRS and MIBG, were not performed systematically in all patients. The low accuracy of locating pancreatic NETs using [
18 F]DOPA PET is explained by the fact that the findings in ten patients with operatively treated insulinoma and b-cell hyperplasia have been published before with good results, and therefore were excluded from this report (Kauhanen et al. 2007) . Furthermore, one argument concerning the use of [
18 F]DOPA in diagnosis suggests that non-functioning tumors may be difficult to detect, since accumulation reflects the secretion pattern of peptide hormones. However, the hypothesis that only amine-producing tumors can be imaged by [
18 F]DOPA PET has to be proved in further studies. According to our findings, even silent tumors without biochemical findings of a NET could be detected by [
18 F]DOPA PET. Recently, several groups have suggested that inhibiting the peripheral decarboxylation can enhance tumor accumulation of HTP and DOPA. The decarboxylase inhibitor carbidopa, given as per oral premedication decreases the renal excretion and, at the same time, increases tumor uptake, hence improving visualization of the tumor (Eriksson et al. 2000 , Orlefors et al. 2006 , Timmers et al. 2007a . The physiological rather high uptake of the pancreas also disappears. In our institution, we have started to use premedication since May 2006 among NET patients except for pancreatic tumors. In this study, only 19 patients had premedication with carbidopa. The finding of increased sensitivity of [
18 F]DOPA PET after carbidopa is important and should be studied further with NETs of various organs. However, its routine use is not recommended with pancreatic tumors (except carcinoids) since pancreatic physiological uptake disappears, and it has not been confirmed that tumor uptake would not also disappear along with this (Kauhanen et al. 2008) . Moreover, a further development has been combined PET-CT, which provides improved anatomical localization. In our study, 70 patients had combined PET-CT, although no statistical difference was observed between the accuracy of .
We have used [ 18 F]DOPA for almost a decade as a tracer in PET imaging of NETs. Our experiences are in accordance with the previous studies. However, all larger previous studies (Becherer et al. 2004 , Hoegerle et al. 2001b , Koopmans et al. 2006 , Montravers et al. 2006 18 F]DOPA PET-CT could be a one-step procedure not only in the staging of a NET but also in the primary diagnosis and follow-up.
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